JUN 1 3 2001

510(K) SUMMARY

Submitted by:

Organogenesis Inc. 150 Dan Road Canton, Massachusetts 02021

Contact

Patrick R. Bilbo

Telephone:

(781) 401-1155

Facsimile:

(781) 401-1109

Date:

April 4, 2001

Device:

Trade Name:

FortaDerm™ Wound Dressing

Common/Usual Name:

Topical Wound Dressing, Wound Management

Biomaterial

Classification Name:

Dressing, Wound (79KMF)

Classification:

Unclassified

Predicate Device:

The relevant predicate device is the SIS Wound Dressing II (K993948) manufactured by Cook Biotech, Incorporated.

Statement of Substantial Equivalence:

The FortaDerm Wound Dressing is similar with respect to intended use, technological characteristics, materials and physical construction to the predicate device in terms of section 510(k) equivalency.

Intended Use:

The FortaDerm Wound Dressing is intended for the management of wounds including: partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds. The device is intended for one-time use.

Device Description:

FortaDerm Wound Dressing consists of a single-layer fenestrated sheet of porcine intestinal collagen. FortaDerm Wound Dressing is supplied dry in sheet form in sizes ranging from 5 x 5 cm to 12 x 36 cm. The device is packaged in sterile, sealed single pouches.

Performance Data:

FortaDerm Wound Dressing was subjected to a number of tests to assess biocompatibility and performance. The device passed the requirements of all tests.



JUN 1 3 2001

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Patrick Bilbo
Director, New Products
Organogenesis, Inc.
150 Dan Road
Canton, Massachusetts 02021

Re: K011026

Trade/Device Name: FortaDerm™ Wound Dressing

Regulatory Class: Unclassified

Product Code: KMF Dated: April 4, 2001 Received: April 4, 2001

Dear Mr. Bilbo:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

Applicant: Organogenesis, Inc.
510(k) Number (if known):